Prisym ID, a provider of regulated content and label management options, has appointed Robert Bowdish as its new director of clinical trials sales, North America.
Prisym ID provides regulated content and label management options designed specifically for life science companies and medical device manufacturers, and intended to improve patient safety and health outcomes whilst ensuring regulatory compliance. With a focus on medical device manufacturing and clinical trials supplies, Prisym ID’s products and technologies are used to assure compliance globally, for more than 10 million medical devices and pharmaceutical products annually.
Mr Bowdish brings wide-ranging healthcare industry sales experience to the role. Having started out working as a pharmaceutical sales representative 26 years ago, he has been specialising in regulatory and clinical software for the past decade. He has joined Prisym ID from Parexel Informatics, where he was initially appointed senior director for solutions consulting, rising to senior director for regulatory clinical solutions, global sales, where he led a team of sales directors working across diverse sectors. Prior to that, he worked as a senior account executive for Truven Health Analytics, which was acquired by IBM Watson Health. He has also worked for Takeda Pharmaceuticals in North America, leading a commercial team of 10 district managers and 100 sales representatives.
Warren Stacey, senior vice president of sales at Prisym ID, commented, ‘He will take the lead driving clinical trials sales in the North American market, building on his relationships with pharma and CROs, demonstrating how our market-leading products can be integrated into a clinical trial supply chain to deliver a compliant labelling solution.’
